![]() ![]() The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™* platform and to locate genetic markers for use in applications other than infectious disease. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). ![]() Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.Ībout Co-Diagnostics, Inc. Webcast: ir. on the Events & Webcasts pageĬonference Call: 84 (domestic) or 41 (international) Because the company owns its platform, it is able to accomplish this faster and more economically, allowing for wider margins while still positioning Co-Diagnostics to be the worldwide low-cost leader of molecular diagnostics services.The conference call and webcast will be available via: It added that it expects to end the year with about 30 million shares outstanding and a corporate effective tax rate of around 18%.Ĭo-Diagnostics’ proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through its enhanced detection of genetic material. The company noted it ended 3Q with $83.9 million in cash and equivalents as of September 30, 2021, an increase of $11.5 million from the end of June this year.Īs well, Co-Diagnostics has provided guidance for its full year of 2021, with the company expecting its revenue to be in the range of $96 million to $100 million and diluted earnings per share forecasted to come in between $1.07 and $1.16. Other highlights for the quarter included pre-tax income of $13.6 million and fully diluted earnings per share of $0.38. “We believe that our diverse international customer base, clean balance sheet and steady cash accumulation, in addition to our high-quality products whose performance has been validated by laboratories and regulatory bodies across the world, help us stand out from the crowd and all contributed to our record sales in Q3,” Egan added. READ: Co-Diagnostics says its Logix Smart COVID-19 test has been approved for sale in the UK “This quarter brought continued growth and strong positioning for sustainability,” Co-Diagnostics (NASDAQ:CODX) CEO Dwight Egan said in a statement. DisclaimerĬo-Diagnostics (NASDAQ:CODX) Inc has announced record third-quarter 2021 revenue of $30.1 million, a 38% year-over-year increase, which the company attributed primarily to sales of its Logix Smart coronavirus (COVID-19) test.Ĭo-Diagnostics (NASDAQ:CODX) also recorded a 67.5% increase in its gross profit for the quarter to $26.8 million, representing 89% of consolidated revenue due to improved product mix as compared to the same period last year. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows. Our human content creators are equipped with many decades of valuable expertise and experience. Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. He previously worked at Investors Digest of Canada, Stockhouse, and. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. ![]() ![]() Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |